Literature DB >> 23484340

Research priorities for Chagas disease, human African trypanosomiasis and leishmaniasis.

.   

Abstract

This report provides a review and analysis of the research landscape for three diseases - Chagas disease, human African trypanosomiasis and leishmaniasis - that disproportionately afflict poor and remote populations with limited access to health services. It represents the work of the disease reference group on Chagas Disease, Human African Trypanosomiasis and Leishmaniasis (DRG3) which was established to identify key research priorities through review of research evidence and input from stakeholders' consultations. The diseases, which are caused by related protozoan parasites, are described in terms of their epidemiology and diseases burden, clinical forms and pathogenesis, HIV coinfection, diagnosis, drugs and drug resistance, vaccines, vector control, and health-care interventions. Priority areas for research are identified based on criteria such as public health relevance, benefit and impact on poor populations and equity, and feasibility. The priorities are found in the areas of diagnostics, drugs, vector control, asymptomatic infection, economic analysis of treatment and vector control methods, and in some specific issues such as surveillance methods or transmission-blocking vaccines for particular diseases. This report will be useful to researchers, policy and decision-makers, funding bodies, implementation organizations, and civil society. This is one of ten disease and thematic reference group reports that have come out of the TDR Think Tank, all of which have contributed to the development of the Global Report for Research on Infectious Diseases of Poverty, available at: www.who.int/tdr/stewardship/global_report/en/index.html.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23484340

Source DB:  PubMed          Journal:  World Health Organ Tech Rep Ser        ISSN: 0512-3054


  92 in total

1.  Leishmanicidal effects of amphotericin B in combination with selenium loaded on niosome against Leishmania tropica.

Authors:  Mahshid Mostafavi; Saeedeh Farajzadeh; Iraj Sharifi; Payam Khazaeli; Hamid Sharifi
Journal:  J Parasit Dis       Date:  2019-01-01

Review 2.  Purinergic receptors and neglected tropical diseases: why ignore purinergic signaling in the search for new molecular targets?

Authors:  P A F Pacheco; L P Dantas; L G B Ferreira; Robson Xavier Faria
Journal:  J Bioenerg Biomembr       Date:  2018-06-07       Impact factor: 2.945

Review 3.  Molecular Diagnosis of Visceral Leishmaniasis.

Authors:  Shyam Sundar; Om Prakash Singh
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

4.  Diversity-oriented synthesis yields a new drug lead for treatment of chagas disease.

Authors:  Sivaraman Dandapani; Andrew R Germain; Ivan Jewett; Sebastian le Quement; Jean-Charles Marie; Giovanni Muncipinto; Jeremy R Duvall; Leigh C Carmody; Jose R Perez; Juan C Engel; Jiri Gut; Danielle Kellar; Jair Lage Siqueira-Neto; James H McKerrow; Marcel Kaiser; Ana Rodriguez; Michelle A Palmer; Michael Foley; Stuart L Schreiber; Benito Munoz
Journal:  ACS Med Chem Lett       Date:  2013-12-29       Impact factor: 4.345

5.  New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.

Authors:  María Gabriela Álvarez; Juan Carlos Ramírez; Graciela Bertocchi; Marisa Fernández; Yolanda Hernández; Bruno Lococo; Constanza Lopez-Albizu; Alejandro Schijman; Carolina Cura; Marcelo Abril; Susana Laucella; Rick L Tarleton; María Ailen Natale; Melisa Castro Eiro; Sergio Sosa-Estani; Rodolfo Viotti
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

6.  Opportunities and challenges in chronic Chagas cardiomyopathy.

Authors:  George A Mensah; Kristin M Burns; Emmanuel K Peprah; Uchechukwu K A Sampson; Michael M Engelgau
Journal:  Glob Heart       Date:  2015-09

7.  Identification of potential trypanothione reductase inhibitors among commercially available β-carboline derivatives using chemical space, lead-like and drug-like filters, pharmacophore models and molecular docking.

Authors:  Jorge Rodríguez-Becerra; Lizethly Cáceres-Jensen; José Hernández-Ramos; Lorena Barrientos
Journal:  Mol Divers       Date:  2017-06-27       Impact factor: 2.943

8.  TcTASV Antigens of Trypanosoma cruzi: Utility for Diagnosis and High Accuracy as Biomarkers of Treatment Efficacy in Pediatric Patients.

Authors:  Noelia Floridia-Yapur; Mercedes Monje-Rumi; Paula Ragone; Juan J Lauthier; Nicolás Tomasini; Anahí Alberti D'Amato; Patricio Diosque; Rubén Cimino; José F Gil; Daniel O Sanchez; Julio R Nasser; Valeria Tekiel
Journal:  Am J Trop Med Hyg       Date:  2019-11       Impact factor: 2.345

9.  Perturbed T cell IL-7 receptor signaling in chronic Chagas disease.

Authors:  M Cecilia Albareda; Damián Perez-Mazliah; M Ailén Natale; Melisa Castro-Eiro; María G Alvarez; Rodolfo Viotti; Graciela Bertocchi; Bruno Lococo; Rick L Tarleton; Susana A Laucella
Journal:  J Immunol       Date:  2015-03-13       Impact factor: 5.422

10.  Detection and Quantification of Viable and Nonviable Trypanosoma cruzi Parasites by a Propidium Monoazide Real-Time Polymerase Chain Reaction Assay.

Authors:  Beatriz Cancino-Faure; Roser Fisa; M Magdalena Alcover; Teresa Jimenez-Marco; Cristina Riera
Journal:  Am J Trop Med Hyg       Date:  2016-05-02       Impact factor: 2.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.